BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34380699)

  • 1. Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer.
    Ng AK; Ng PY; Ip A; Cheung KS; Siu CW
    BMJ Open Gastroenterol; 2021 Aug; 8(1):. PubMed ID: 34380699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
    Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    Brusselaers N; Wahlin K; Engstrand L; Lagergren J
    BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of gastric cancer among long-term proton pump inhibitor users: a population-based cohort study.
    Kim JW; Jung HK; Lee B; Shin CM; Gong EJ; Hong J; Youn YH; Lee KJ
    Eur J Clin Pharmacol; 2023 Dec; 79(12):1699-1708. PubMed ID: 37861752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
    Gong EJ; Jung HK; Lee B; Hong J; Kim JW; Shin CM; Youn YH; Lee KJ
    Aliment Pharmacol Ther; 2023 Oct; 58(7):668-677. PubMed ID: 37589510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
    Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
    [No Abstract]   [Full Text] [Related]  

  • 8. Association Between Proton Pump Inhibitor Use and Risk of Fracture in Children.
    Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
    JAMA Pediatr; 2020 Jun; 174(6):543-551. PubMed ID: 32176276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
    Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
    JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention.
    Nakayama A; Morita H; Ando J; Fujita H; Ohtsu H; Nagai R
    Heart Vessels; 2013 May; 28(3):292-300. PubMed ID: 22460241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
    Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
    Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
    Serbin MA; Guzauskas GF; Veenstra DL
    J Manag Care Spec Pharm; 2016 Aug; 22(8):939-47. PubMed ID: 27459657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis.
    Zhu P; Gao Z; Tang XF; Xu JJ; Zhang Y; Gao LJ; Chen J; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Chin Med J (Engl); 2017 Dec; 130(24):2899-2905. PubMed ID: 29237921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions.
    Komarov AL; Shakhmatova OO; Muraseeva VG; Novikova ES; Guskova EV; Panchenko EP
    Ter Arkh; 2018 Sep; 90(9):92-100. PubMed ID: 30701742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
    Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
    JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
    Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
    Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
    Bhurke SM; Martin BC; Li C; Franks AM; Bursac Z; Said Q
    Pharmacotherapy; 2012 Sep; 32(9):809-18. PubMed ID: 22744772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
    Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K;
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.